Contrasting Nuwellis (NASDAQ:NUWE) and Vivani Medical (NASDAQ:VANI)

Nuwellis (NASDAQ:NUWE) and Vivani Medical (NASDAQ:VANI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 2.6% of Nuwellis shares are held by company insiders. Comparatively, 55.6% of Vivani Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Nuwellis and Vivani Medical’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.86 million	0.44	-$20.21 million	($8.30)	-0.03
Vivani Medical	N/A	N/A	-$25.65 million	($0.50)	-2.56

Nuwellis has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuwellis and Vivani Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuwellis	-202.97%	-316.90%	-166.33%
Vivani Medical	N/A	-93.91%	-47.76%

Analyst Recommendations

This is a summary of current recommendations and price targets for Nuwellis and Vivani Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	0	1	0	0	2.00
Vivani Medical	0	0	0	0	N/A

Volatility & Risk

Nuwellis has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 3.22, indicating that its stock price is 222% more volatile than the S&P 500.

Summary

Vivani Medical beats Nuwellis on 7 of the 10 factors compared between the two stocks.

About Nuwellis

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

About Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.